Terms: = Kidney tumors AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR
23 results:
1. A rare case of extrarenal Wilms tumor of the uterine corpus: comprehensive genomic profile and review of the literature.
Alessandrini L; Guerriero A; Munari G; Del Forno B; Santoro L; Marchetti M; Nardin M; Tozzi R; Fassan M; Dei Tos AP
Pathologica; 2023 Dec; 115(6):333-340. PubMed ID: 38180141
[TBL] [Abstract] [Full Text] [Related]
2. Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin.
Liang WW; Lu RJ; Jayasinghe RG; Foltz SM; Porta-Pardo E; Geffen Y; Wendl MC; Lazcano R; Kolodziejczak I; Song Y; Govindan A; Demicco EG; Li X; Li Y; Sethuraman S; Payne SH; Fenyö D; Rodriguez H; Wiznerowicz M; Shen H; Mani DR; Rodland KD; Lazar AJ; Robles AI; Ding L;
Cancer Cell; 2023 Sep; 41(9):1567-1585.e7. PubMed ID: 37582362
[TBL] [Abstract] [Full Text] [Related]
3. [Expression and significance of fibroblast growth factor receptor 2 in clear cell renal cell carcinoma].
Cai TY; Zhu ZP; Xu CR; Ji X; Lv TD; Guo ZK; Lin J
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):628-635. PubMed ID: 35950384
[TBL] [Abstract] [Full Text] [Related]
4. Differences in genomic profile of high-grade urothelial carcinoma according to tumor location.
Park CK; Cho NH
Urol Oncol; 2022 Mar; 40(3):109.e1-109.e9. PubMed ID: 34663543
[TBL] [Abstract] [Full Text] [Related]
5. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
[TBL] [Abstract] [Full Text] [Related]
6. Topographic distribution of first landing sites of lymphatic metastases from patients with renal cancer.
Kuusk T; Zondervan P; Lagerveld B; Rosenzweig B; Raman A; Blok JM; de Bruijn R; Graafland N; Hendricksen K; Capitanio U; Minervini A; Ljungberg B; Horenblas S; Bex A
Urol Oncol; 2020 May; 38(5):521-525. PubMed ID: 32139289
[TBL] [Abstract] [Full Text] [Related]
7. Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib.
Vanmechelen M; Lambrechts D; Van Brussel T; Verbiest A; Couchy G; Schöffski P; Dumez H; Debruyne PR; Lerut E; Machiels JP; Richard V; Albersen M; Verschaeve V; Oudard S; Méjean A; Wolter P; Zucman-Rossi J; Beuselinck B
Clin Genitourin Cancer; 2019 Apr; 17(2):e235-e246. PubMed ID: 30527746
[TBL] [Abstract] [Full Text] [Related]
8. MiR-148b-3p inhibits renal carcinoma cell growth and pro-angiogenic phenotype of endothelial cell potentially by modulating FGF2.
Zhang H; Ye Q; Du Z; Huang M; Zhang M; Tan H
Biomed Pharmacother; 2018 Nov; 107():359-367. PubMed ID: 30099339
[TBL] [Abstract] [Full Text] [Related]
9. Relationship and Predictive Role of the Dual Expression of FGFR and IL-8 in Metastatic Renal Cell Carcinoma Treated with Targeted Agents.
Iacovelli R; DE Tursi M; Mosillo C; Ciardi A; Carella C; Natoli C; Naso G; Cortesi E
Anticancer Res; 2018 May; 38(5):3105-3110. PubMed ID: 29715147
[TBL] [Abstract] [Full Text] [Related]
10. Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma.
Go H; Kang MJ; Kim PJ; Lee JL; Park JY; Park JM; Ro JY; Cho YM
Pathol Oncol Res; 2019 Jan; 25(1):51-58. PubMed ID: 28963640
[TBL] [Abstract] [Full Text] [Related]
11. fgfr2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma.
Tsimafeyeu I; Khasanova A; Stepanova E; Gordiev M; Khochenkov D; Naumova A; Varlamov I; Snegovoy A; Demidov L
Clin Transl Oncol; 2017 Feb; 19(2):265-268. PubMed ID: 27379982
[TBL] [Abstract] [Full Text] [Related]
12. Preoperative Plasma Fibrinogen Level Represents an Independent Prognostic Factor in a Chinese Cohort of Patients with Upper Tract Urothelial Carcinoma.
Zhang B; Song Y; Jin J; Zhou LQ; He ZS; Shen C; He Q; Li J; Liu LB; Wang C; Chen XY; Fan Y; Hu S; Zhang L; Yu W; Han WK
PLoS One; 2016; 11(3):e0150193. PubMed ID: 26930207
[TBL] [Abstract] [Full Text] [Related]
13. Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses.
Ford PA; Grant SJ; Mick R; Keck G
J Clin Oncol; 2015 May; 33(15):1674-9. PubMed ID: 25870085
[TBL] [Abstract] [Full Text] [Related]
14. Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms.
van der Mijn JC; Mier JW; Broxterman HJ; Verheul HM
Drug Resist Updat; 2014; 17(4-6):77-88. PubMed ID: 25457974
[TBL] [Abstract] [Full Text] [Related]
15. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma.
Rosenberg JE; Bambury RM; Van Allen EM; Drabkin HA; Lara PN; Harzstark AL; Wagle N; Figlin RA; Smith GW; Garraway LA; Choueiri T; Erlandsson F; Laber DA
Invest New Drugs; 2014 Feb; 32(1):178-87. PubMed ID: 24242861
[TBL] [Abstract] [Full Text] [Related]
16. Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors.
Wöhrle S; Weiss A; Ito M; Kauffmann A; Murakami M; Jagani Z; Thuery A; Bauer-Probst B; Reimann F; Stamm C; Pornon A; Romanet V; Guagnano V; Brümmendorf T; Sellers WR; Hofmann F; Roberts CW; Graus Porta D
PLoS One; 2013; 8(10):e77652. PubMed ID: 24204904
[TBL] [Abstract] [Full Text] [Related]
17. Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib.
Beuselinck B; Karadimou A; Lambrechts D; Claes B; Wolter P; Couchy G; Berkers J; Paridaens R; Schöffski P; Méjean A; Verkarre V; Lerut E; de la Taille A; Tourani JM; Bigot P; Linassier C; Négrier S; Berger J; Patard JJ; Zucman-Rossi J; Oudard S
Br J Cancer; 2013 Mar; 108(4):887-900. PubMed ID: 23462807
[TBL] [Abstract] [Full Text] [Related]
18. Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas.
Zhao Q; Caballero OL; Davis ID; Jonasch E; Tamboli P; Yung WK; Weinstein JN; ; Strausberg RL; Yao J
Clin Cancer Res; 2013 May; 19(9):2460-72. PubMed ID: 23444225
[TBL] [Abstract] [Full Text] [Related]
19. Comparison of the 2002 and 2010 TNM classification systems regarding outcome prediction in clear cell and papillary renal cell carcinoma.
Pichler M; Hutterer GC; Chromecki TF; Jesche J; Kampel-Kettner K; Groselj-Strele A; Hoefler G; Pummer K; Zigeuner R
Histopathology; 2013 Jan; 62(2):237-46. PubMed ID: 23020176
[TBL] [Abstract] [Full Text] [Related]
20. The role of pharmacogenomics in metastatic renal cell carcinoma.
Castellano D; Virizuela JA; Cruz J; Sepulveda JM; Sáez MI; Paz-Ares L
Cancer Metastasis Rev; 2012 Sep; 31 Suppl 1():S29-32. PubMed ID: 22723081
[TBL] [Abstract] [Full Text] [Related]
[Next]
